Notice of Allowability

Application No. 09/922,221 Applicant(s)

Evans

Examiner

Arun Chakrabarti

1634

Art Unit



The MAILING DATE of this communication appears on the cover sheet with the correspondence address	
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. The initiative of the Office or upon petition by the applicant. See 37 CFR 1.3	e communication will be mailed in due course. This application is subject to withdrawal from issue at
1. X This communication is responsive to 5/27/03	
2. X The allowed claim(s) is/are 1-23	
3. X The drawings filed on Aug 2, 2001 are accepted by the	Examiner.
4. Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).	
a) \square All b) \square Some* c) \square None of the:	
1. Certified copies of the priority documents have been received	ved.
2. Certified copies of the priority documents have been received.	ved in Application No
Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received:	
5. Acknowledgement is made of a claim for domestic priority under	
(a) ☐ The translation of the foreign language provisional application has been received.	
6. Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communited below. Failure to timely comply will result in ABANDONMENT of this EXTENDABLE.	nication to file a reply complying with the requirements application. THIS THREE-MONTH PERIOD IS NOT
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note th INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) v	
8. CORRECTED DRAWINGS must be submitted.	
(a) 🗌 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached	
1) \square hereto or 2) \square to Paper No	
(b) including changes required by the proposed drawing correction approved by the examiner.	on filed, which has been
(c) including changes required by the attached Examiner's Amendment/Comment or in the Office action of Paper No	
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should each sheet. The drawings should be filed as a separate paper with a transmitte	
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOG attached Examiner's comment regarding REQUIREMENT FOR THE	
Attachment(s)	
1 Notice of References Cited (PTO-892)	2 Notice of Informal Patent Application (PTO-152)
3 Notice of Draftsperson's Patent Drawing Review (PTO-948)	4 🕅 Interview Summary (PTO-413), Paper No.0603 .
5 Information Disclosure Statement(s) (PTO-1449), Paper No(s).	6 Examiner's Amendment/Comment
7 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8 🛛 Examiner's Statement of Reasons for Allowance
9 Other	

Application/Control Number: 09/922,221

Art Unit: 1634

Reasons for Allowance

- 1. The following is an examiner's statement of reasons for allowance: The present invention is directed to a method of assembling a double-stranded polynucleotide comprising the steps of:
- a) selecting a partially double-stranded initiating oligonucleotide, wherein the initiating oligonucleotide comprises a at least one overhang;
- b) contacting the partially double-stranded initiating oligonucleotide with a next most terminal double-stranded oligonucleotide, wherein the next most terminal double-stranded initiating oligonucleotide is contiguous with the initiating oligonucleotide and comprises at least one overhang, and wherein at least one overhang of the next most terminal double-stranded oligonucleotide is complementary to at least one overhang of the initiating oligonucleotide;
- c) repeating step (b) to sequentially add the next most terminal double-stranded oligonucleotide to the extended initiating oligonucleotide, whereby the double-stranded oligonucleotide is synthesized.

Although Beattie et al., (Biotechnology and Applied Biochemistry, (1988), Vol. 10, pages 510-521). teaches a method of assembling a double-stranded polynucleotide, Beattie et al. does not teach the sequential addition of a next most terminal double-stranded oligonucleotide of step (b).

In view of the absence of either teaching or suggestion of such a method of assembling a double-stranded polynucleotide comprising the steps of:

a) selecting a partially double-stranded initiating oligonucleotide, wherein the initiating oligonucleotide comprises a at least one overhang;

b) contacting the partially double-stranded initiating oligonucleotide with a next most terminal double-stranded oligonucleotide, wherein the next most terminal double-stranded initiating oligonucleotide is contiguous with the initiating oligonucleotide and comprises at least one overhang, and wherein at least one overhang of the next most terminal double-stranded oligonucleotide is complementary to at least one overhang of the initiating oligonucleotide;

c) repeating step (b) to sequentially add the next most terminal double-stranded oligonucleotide to the extended initiating oligonucleotide, whereby the double-stranded oligonucleotide is synthesized., the present invention is novel and non-obvious.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful the examiner's

Application/Control Number: 09/922,221

Art Unit: 1634

supervisor, Gary Benzion, can be reached on (703) 308-1119. The fax phone number for this Group is (703) 746-4979. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

June 27, 2003

ETHAN WHISENANT PRIMARY EXAMINER